An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback